Center for Retina and Macular Disease | Winter Haven, FL

Research site

(Unclaimed)

Location

250 Avenue K Southwest Suite 200, Winter Haven, Florida, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

Aflibercept

Abicipar Pegol

SF0166

Triamcinolone Acetonide

APL-2

THR-687

ABP 938

DHA

Ocriplasmin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 48 total trials

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (ELARA)

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Active, not recruiting

Neovascular Age-Related Macular Degeneration

Diabetic Macular Edema

Drug: Aflibercept 8 mg

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (...

Enrolling

Wet Age-related Macular Degeneration

Drug: Tarcocimab tedromer

Drug: Aflibercept

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) (GLOW2)

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.

Active, not recruiting

Diabetic Retinopathy

Drug: Tarcocimab

Other: Sham injection

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Active, not recruiting

Macular Edema Secondary to Retinal Vein Occlusion

Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg

Drug: Sham

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling

Diabetic Retinopathy

Drug: BI 764524

Drug: Aflibercept (Eylea®) - US only

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling

Wet Age-related Macular Degeneration

WetAMD

Biological: Aflibercept (EYLEA®)

Genetic: ABBV-RGX-314 Dose 2

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NOVA-1)

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in...

Enrolling

Neovascular Age-related Macular Degeneration (nAMD)

Drug: AR-14034 SR implant lower dose

Drug: AR-14034 SR implant higher dose